Connecticut 2017 Regular Session

Connecticut House Bill HB07118

Introduced
2/22/17  
Introduced
2/22/17  
Refer
2/22/17  
Refer
2/22/17  
Report Pass
3/7/17  
Report Pass
3/7/17  
Refer
3/17/17  
Refer
3/17/17  
Report Pass
3/23/17  
Report Pass
3/23/17  
Refer
4/4/17  
Report Pass
4/10/17  
Report Pass
4/10/17  
Engrossed
5/23/17  
Engrossed
5/23/17  

Caption

An Act Concerning Biological Products.

Impact

This bill has significant implications for state laws governing pharmacy practices, particularly regarding how biological products are dispensed. It sets forth clear guidelines about the responsibilities of pharmacists in notifying both patients and prescribers when a substitution has been made. By allowing substitutions, the bill aims to streamline the dispensing process and assist in reducing healthcare costs, which could ultimately benefit patients through lower medication expenses and increased availability of essential drugs.

Summary

House Bill 07118, concerning biological products, aims to standardize the process by which pharmacists substitute prescribed biological products with interchangeable ones. The bill allows pharmacists to make these substitutions unless explicitly instructed otherwise by the prescriber or if the prescriber indicates that a specific brand is medically necessary. The intended outcome is to enhance accessibility to medications while potentially reducing costs for consumers by enabling the use of more affordable alternatives.

Sentiment

The sentiment surrounding HB 07118 appears to be largely supportive among legislators concerned with healthcare costs and patient access to medications. However, there are some concerns voiced by certain stakeholders about the potential implications for patient safety and the quality of care. Opponents may worry that automatic substitutions could lead to confusion or diminish the trust between patients and their healthcare providers. Overall, the discussion about the bill reflects a balance between economic considerations and patient welfare.

Contention

Notable points of contention include the degree of latitude given to pharmacists in substituting prescribed drugs without prescriber consent, especially in the context of drugs used to treat conditions like epilepsy. Critics argue this could result in patients receiving medications that may not adequately address their specific needs or conditions. The requirement for pharmacists to post signage about substitution practices has also sparked discussion regarding transparency and patient awareness as it relates to medication management.

Companion Bills

No companion bills found.

Similar Bills

CT SB00197

An Act Concerning Biological Products.

CT SB00313

An Act Concerning Biological Products.

TX HB542

Relating to the prescription and pharmaceutical substitution of biological products.

TX SB190

Relating to the prescription and pharmaceutical substitution of biological products.

TX HB751

Relating to the prescription and pharmaceutical substitution of biological products; amending provisions subject to a criminal penalty.

TX SB542

Relating to the prescription and pharmaceutical substitution of biological products.

OR SB441

Relating to biological products.

KY HB346

AN ACT relating to biosimilar medicines.